Capricor Therapeutics Faces Class Action Lawsuit Over Alleged Securities Fraud
On August 24, 2026, the renowned law firm Berger Montague PC announced the launch of a class action lawsuit against Capricor Therapeutics, Inc. (NASDAQ: CAPR), aimed at investors who purchased or acquired Capricor's securities during the period from December 17, 2025, to July 26, 2026. This action arises amidst significant allegations of securities fraud that have unfolded in recent months.
Capricor Therapeutics, a biotechnology firm headquartered in San Diego, is primarily recognized for its lead product candidate, Deramiocel, which is a cell therapy designed to ameliorate the condition of patients suffering from Duchenne's muscular dystrophy. However, the lawsuit centers around events that transpired shortly before the scheduled meeting of the U.S. Food and Drug Administration's (FDA) advisory committee on July 29, 2026.
On the morning of July 27, 2026, the FDA released briefing documents that illuminated inconsistencies in Capricor's submission for a biologics license application (BLA) regarding Deramiocel. The documents stated that Capricor had modified its pre-specified statistical analysis plan (SAP). Alarmingly, the revisions included adjustments that allegedly were not included in the version of the SAP submitted for FDA review prior to the BLA submission. This omission has led to grave concerns, as the FDA expressed that it did not find the company's analysis scientifically justified, thus casting a long shadow over the perceived efficacy of Deramiocel.
As the implications of the FDA's findings circulated, Capricor's stock plummeted by $12.70 per share—a staggering 64% drop—closing at $7.00 per share following the announcement of the adverse documentation from the FDA. This significant decline in stock value raises considerable alarm for investors who may have been misled or deprived of essential information that could affect their financial decisions.
Investors are urged to act quickly to determine their rights related to this class action. The deadline for those interested in becoming lead plaintiff representatives is set for September 28, 2026. Those impacted should navigate their next steps carefully and seek legal guidance if they feel entitled to recompense or wish to be part of the ongoing litigation.
Berger Montague has positioned itself as one of the leading law firms in complex civil litigation, specializing in class actions and mass tort cases across the United States. With a proven track record, the firm has secured over $50 billion in recoveries for its clients and played pivotal roles in multiple precedent-setting cases over its 55 years of operation.
For individuals interested in learning more about this developing case or exploring their rights as CAPRICOR investors, they are encouraged to reach out directly to Berger Montague. Andrew Abramowitz and Caitlin Adorni are available via the firm's contact details, providing necessary assistance to those navigating this complex situation.
The unfolding events around Capricor Therapeutics serve as a stark reminder of the critical importance of transparency and integrity in the biotech sector, particularly when substantial investments hinge on allegations of misleading data and reports. This lawsuit could set an important precedent and highlights the vigilance needed in investor relations and corporate governance. As the story develops, investors and stakeholders within the sector are keenly observing how these accusations will be addressed in the court system, and what outcomes may arise from this pivotal case in the world of biotechnology and securities law.
Capricor Therapeutics, a biotechnology firm headquartered in San Diego, is primarily recognized for its lead product candidate, Deramiocel, which is a cell therapy designed to ameliorate the condition of patients suffering from Duchenne's muscular dystrophy. However, the lawsuit centers around events that transpired shortly before the scheduled meeting of the U.S. Food and Drug Administration's (FDA) advisory committee on July 29, 2026.
On the morning of July 27, 2026, the FDA released briefing documents that illuminated inconsistencies in Capricor's submission for a biologics license application (BLA) regarding Deramiocel. The documents stated that Capricor had modified its pre-specified statistical analysis plan (SAP). Alarmingly, the revisions included adjustments that allegedly were not included in the version of the SAP submitted for FDA review prior to the BLA submission. This omission has led to grave concerns, as the FDA expressed that it did not find the company's analysis scientifically justified, thus casting a long shadow over the perceived efficacy of Deramiocel.
As the implications of the FDA's findings circulated, Capricor's stock plummeted by $12.70 per share—a staggering 64% drop—closing at $7.00 per share following the announcement of the adverse documentation from the FDA. This significant decline in stock value raises considerable alarm for investors who may have been misled or deprived of essential information that could affect their financial decisions.
Investors are urged to act quickly to determine their rights related to this class action. The deadline for those interested in becoming lead plaintiff representatives is set for September 28, 2026. Those impacted should navigate their next steps carefully and seek legal guidance if they feel entitled to recompense or wish to be part of the ongoing litigation.
Berger Montague has positioned itself as one of the leading law firms in complex civil litigation, specializing in class actions and mass tort cases across the United States. With a proven track record, the firm has secured over $50 billion in recoveries for its clients and played pivotal roles in multiple precedent-setting cases over its 55 years of operation.
For individuals interested in learning more about this developing case or exploring their rights as CAPRICOR investors, they are encouraged to reach out directly to Berger Montague. Andrew Abramowitz and Caitlin Adorni are available via the firm's contact details, providing necessary assistance to those navigating this complex situation.
The unfolding events around Capricor Therapeutics serve as a stark reminder of the critical importance of transparency and integrity in the biotech sector, particularly when substantial investments hinge on allegations of misleading data and reports. This lawsuit could set an important precedent and highlights the vigilance needed in investor relations and corporate governance. As the story develops, investors and stakeholders within the sector are keenly observing how these accusations will be addressed in the court system, and what outcomes may arise from this pivotal case in the world of biotechnology and securities law.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.